
IF YOU ARE PREVIOUSLY UNTREATED WITH ADVANCED KIDNEY CANCER
Working together for you
What is CABOMETYX® (cabozantinib)?
CABOMETYX is a prescription medicine used to treat:
- People with kidney cancer (renal cell carcinoma). CABOMETYX may be used:
- Alone to treat people with renal cell carcinoma (RCC) that has spread (advanced RCC)
- In combination with nivolumab when your cancer has spread (advanced RCC), and you have not already had a treatment for your advanced RCC
- People with liver cancer (hepatocellular carcinoma) who have been previously treated with the medicine sorafenib.
It is not known if CABOMETYX is safe and effective in children.
How CABOMETYX may help
In a clinical study, CABOMETYX was given to people with advanced kidney cancer as a first treatment, with another medicine, OPDIVO® (nivolumab). Other people in the study received a different medicine, sunitinib.*
People stayed on treatment until their tumors started to grow, or they had a side effect that could not be managed.
-
323 people took CABOMETYX
(orally) + OPDIVO (infusion) -
328 people took
sunitinib (orally)
Each person’s results with CABOMETYX may be different.
*Sunitinib is a medication used to treat people with advanced kidney cancer.
CABOMETYX + OPDIVO results showed that:

People were able to live 2x LONGER without their tumor growing or spreading
People who took CABOMETYX + OPDIVO were able to live without their tumor progressing for a median† of 16.6 months compared to 8.3 months for people who took sunitinib.
†Median is the middle value in a set of the measurements—for some it was shorter; for others, longer.

TWICE AS MANY PEOPLE had meaningful reductions‡ in their tumor size
55.7% of people who took CABOMETYX + OPDIVO had reductions in tumor size, compared to 27.1% of people taking sunitinib.
Nearly TWICE AS MANY PEOPLE saw their tumors disappear completely (complete response)
CABOMETYX + OPDIVO
8% complete response
48% partial response
sunitinib
4.6% complete response
23% partial response
‡Meaningful reductions defined as the combination of complete response (the disappearance of signs of cancer in response to treatment), and partial response (a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.)
CABOMETYX may cause serious side effects, including:
Bleeding (hemorrhage). CABOMETYX can cause severe bleeding that may lead to death. Tell your healthcare provider right away if you get any signs of bleeding during treatment with CABOMETYX, including:
- Coughing up blood or blood clots
- Vomiting blood or if your vomit looks like coffee grounds
- Red or black (looks like tar) stools
- Menstrual bleeding that is heavier than normal
- Any unusual or heavy bleeding
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
See additional safety information below.
If your healthcare provider prescribes CABOMETYX + OPDIVO, read the Medication Guide that comes with OPDIVO.
Support for you: Patient and caregiver resources


If you are taking CABOMETYX + OPDIVO and have questions about OPDIVO, please call 1-855-OPDIVO-1 (1-855-673-4861) or visit OPDIVO.com
OPDIVO® and the related logo is a registered trademark of Bristol-Myers Squibb Company.